excerpt from a filing made today.....
BZ Group Holding Limited, by this Amendment No. 2, hereby amends the
report on Schedule 13D, originally filed on December 16, 1999 by Pharma Vision
AG and BZ Group Holding Limited, relating to the Common Stock, par value $0.001
per share (the "Common Stock"), of Tularik Inc., a Delaware corporation (the
"Company"), as previously amended by Amendment No. 1 thereto, originally filed
on February 8, 2001 (such Schedule 13D, as amended, the "Schedule 13D").
This Amendment No. 2 to the Schedule 13D is being filed solely to
report the following with respect to Item 5 (Interest in Securities of the
Issuer):
On July 30, 2002, BZ Group Holding Limited sold all of its holdings of
registered shares of Pharma Vision AG and Spezialitaten Vision AG to Cantonal
Bank of Zurich pursuant to a Purchase Agreement between BZ Group Holding Limited
and Cantonal Bank of Zurich. Accordingly, as of July 30, 2002, BZ Group Holding
Limited had no beneficial ownership of any Common Stock of the Company, except
that BZ Group Holding Limited directly held 800,000 shares of the Company's
Common Stock, representing approximately 1.6% of Common Stock outstanding.
Therefore, as of July 30, 2002, BZ Group Holding Limited ceased to be the
beneficial owner of more than five percent of the Common Stock. |
